Bicalutamide treatment for locally advanced prostate cancer

In men with locally advanced prostate cancer, bicalutamide 150 mg monotherapy provides a similar disease outcome to medical or surgical castration. However, castration is associated with loss of sexual interest and function, decreased energy and an increased risk of osteoporotic fractures. Bicalutamide 150 mg monotherapy has less impact on sexual interest and physical capacity than castration.